GFT505: Phase I data

In the double-blind Phase I GFT505-109-6 trial in 30 healthy volunteers, 100 mg/day oral GFT505 significantly reduced fasting free fatty acid plasma concentration by 14% from baseline to day 14 (p=0.0...